Xiaomo: China Biotech's ESMO catalyst can verify local innovation, the first choice for local innovation, Colunbotai Biotech (06990), and Cinda Biotech (01801)
The Zhitong Finance App learned that J.P. Morgan Chase released a research report saying that close to the European Society of Medical Oncology (ESMO) annual meeting, the trip was previewing key updates from many Chinese biotech and pharmaceutical companies covered, believing that several catalysts are expected to boost Chinese biotech stocks and further verify the strength of China's original innovations in the fields of bispecific antibodies, ADCs, and targeted tumors. More than 20 Chinese biotech stocks covered by the bank fell 4.4% last week, outperforming the Hang Seng Index, which rose 1.8%. In the biotech sector, the bank's first choice is still Columbotai Biotech (06990) and Cinda Biotech (01801), believing that the two have rich catalytic paths to ESMO and beyond; the bank also had a more positive view of Health Biotech because AstraZeneca (AZN.US) invested 2 billion US dollars in Kangfang Biotech (09926) US partner Summit (SMMT.US).
The bank pointed out that the early asset readings of Intosilicon Intelligence (03696) can be used as a relevant data point for the AIDD (AIDD) platform. The late-stage assets of Hengrui Pharmaceuticals (01276) and Hanson Pharmaceuticals (03692) are still the focus of investors' attention on the medium term growth engine. The ESMO paper abstract is expected to be released on October 18 at 6 p.m. EST. The poster is expected to be launched on October 23, and the ESMO conference will be held from October 23 to 27.
Collumbott's SAC-TMT has two key phase III catalysts, including global phase 3 trofuse-005 for endometrial cancer and first-line PD-L1 negative non-squamous non-small cell lung cancer Chinese stage 3 optitrop-lung06. Investors focus on whether the data can further verify the activity of SAC-TMT across tumors, support global registration strategies, and strengthen confidence in its ADC platform and cooperation with MSD.
Cinda Biotech's most important catalyst is CLDN18.2 ADC IBI343 (arcotatug tavetecan), the Chinese registered third-line gastric cancer G-HOPE-001 data, which will be published in the latest breakthrough oral report; the bank is also concerned about IBI363 updates on first-line gastric cancer/gastroesophageal junction adenocarcinoma and first-line non-small cell lung cancer, as well as other ADC readings.
Kang Fang Biotech focuses on ivonescimab's Harmoni-GI1 first-line advanced biliary tract cancer stage 3 data, with contrast valiumab plus chemotherapy; the study estimates that the overall survival risk ratio is expected to reach 0.6 or less. If confirmed, it will be the best overall survival risk ratio data obtained by ivonescimab in the phase III study in China.
The bank also indicated that ISM6331, a pan-TEAD inhibitor designed by Insili's intelligent artificial intelligence, will publish a quick oral report focusing on safety, dose escalation, and early efficacy signals. Hengrui Pharmaceutical's update covers KRAS G12D, HER2 ADC and HER3 ADC projects, including HRS-4642, SHR-A1811, and SHR-A2009, which is expected to attract investors' attention to whether it can support medium-term growth and global expansion.
For Hanson Pharmaceuticals, Ris-Rez (HS-20093) stage 3 osteosarcoma data is still a key late-stage catalyst, and ADCs such as HS-20122 have also been updated.
The above companies all gave the bank an “increase in wealth” rating.